MedPath

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: INSULIN GLARGINE (HOE901)
Registration Number
NCT00965549
Lead Sponsor
Sanofi
Brief Summary

The primary objective is to demonstrate the non-inferiority at six months of a basal plus one insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin regimen (NovoMix 30) at controlling glycosylated haemoglobin (HbA1c) in type 2 diabetes.

The secondary objective are:

* To compare the proportion of patients in each treatment group reaching HbA1c target (\< 7%) at the end of the treatment period

* To compare the rates of hypoglycaemia (total, severe, nocturnal)

* To compare the change in body weight from visit 10 to visit 24

* To compare the change in diabetes specific quality of life and other patient reported outcomes from visit 10 to visit 24

* Diabetes Treatment Satisfaction Questionnaire - status and change (DTSQs+c)

* Audit of Diabetes-Dependent Quality of Life (ADDQoL) questionnaire

* Insulin Treatment Satisfaction Questionnaire (ITSQ)

* EuroQoL 5 Dimensions (EQ5D) questionnaire

* To record the change in the daily dose of insulin from visit 2 to visit 10 and visit 10 to visit 24

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
463
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lantus + Apidra basal plus oneInsulin GlulisineBefore randomization (common with arm 2): A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy. 8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued. After randomization: 24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day
Lantus + Apidra basal plus oneINSULIN GLARGINE (HOE901)Before randomization (common with arm 2): A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy. 8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued. After randomization: 24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day
NovoMix 30 BiphasicInsulin aspartBefore randomization (common with arm 1): A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy. 8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued. After randomization: 24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)
Primary Outcome Measures
NameTimeMethod
Glycosylated Haemoglobin (HbA1c)At week 7 and week 32
Secondary Outcome Measures
NameTimeMethod
Hypoglycaemia (total, severe and nocturnal)At week 0 and week 32
Diabetes specific quality of life measured using ADDQoL (Audit of Diabetes-Dependent Quality of Life questionnaire) and other patient reported outcomes measured using EQ5D (EuroQoL 5 Dimensions questionnaire)Week 8 and week 32
WeightAt week 8 and week 32

Trial Locations

Locations (74)

Investigational Site Number 826-130

🇬🇧

Bristol, United Kingdom

Investigational Site Number 826-149

🇬🇧

Barnsley, United Kingdom

Investigational Site Number 826-136

🇬🇧

Bradford, United Kingdom

Investigational Site Number 209

🇦🇺

Milton, Australia

Investigational Site Number 826-106

🇬🇧

Bournemouth, United Kingdom

Investigational Site Number 826-141

🇬🇧

Cheadle, United Kingdom

Investigational Site Number 826-127

🇬🇧

Glasgow, United Kingdom

Investigational Site Number 826-164

🇬🇧

Hereford, United Kingdom

Investigational Site Number 826-122

🇬🇧

Livingston, United Kingdom

Investigational Site Number 826-116

🇬🇧

Salford, United Kingdom

Investigational Site Number 826-166

🇬🇧

London, United Kingdom

Investigational Site Number 826-110

🇬🇧

Llantrisant, United Kingdom

Investigational Site Number 826-137

🇬🇧

Manchester, United Kingdom

Investigational Site Number 204

🇦🇺

Campbelltown, Australia

Investigational Site Number 205

🇦🇺

Campbelltown, Australia

Investigational Site Number 210

🇦🇺

Daw Park, Australia

Investigational Site Number 214

🇦🇺

Douglas, Australia

Investigational Site Number 201

🇦🇺

Caulfield, Australia

Investigational Site Number 203

🇦🇺

Heidelberg, Australia

Investigational Site Number 206

🇦🇺

Herston, Australia

Investigational Site Number 211

🇦🇺

Maroubra, Australia

Investigational Site Number 207

🇦🇺

Meadowbrook, Australia

Investigational Site Number 212

🇦🇺

Melbourne, Australia

Investigational Site Number 213

🇦🇺

Nowra, Australia

Investigational Site Number 202

🇦🇺

Parkville, Australia

Investigational Site Number 208

🇦🇺

Southport, Australia

Investigational Site Number 826-109

🇬🇧

Aberdeen, United Kingdom

Investigational Site Number 826-126

🇬🇧

High Wycombe, United Kingdom

Investigational Site Number 826-102

🇬🇧

Hull, United Kingdom

Investigational Site Number 826-140

🇬🇧

Newcastle upon Tyne, United Kingdom

Investigational Site Number 826-143

🇬🇧

Scunthorpe, United Kingdom

Investigational Site Number 826-104

🇬🇧

Sheffield, United Kingdom

Investigational Site Number 826-118

🇬🇧

Ashton-under-Lyne, United Kingdom

Investigational Site Number 826-157

🇬🇧

Ayr, United Kingdom

Investigational Site Number 826-135

🇬🇧

Bath, United Kingdom

Investigational Site Number 826-124

🇬🇧

Birmingham, United Kingdom

Investigational Site Number 826-150

🇬🇧

Birmingham, United Kingdom

Investigational Site Number 826-114

🇬🇧

Bury St Edmunds, United Kingdom

Investigational Site Number 826-132

🇬🇧

Carmarthen, United Kingdom

Investigational Site Number 826-112

🇬🇧

Chesterfield, United Kingdom

Investigational Site Number 826-147

🇬🇧

Chester, United Kingdom

Investigational Site Number 826-152

🇬🇧

Chichester, United Kingdom

Investigational Site Number 826-159

🇬🇧

Cleveleys, United Kingdom

Investigational Site Number 826-119

🇬🇧

Cornwall, United Kingdom

Investigational Site Number 826-113

🇬🇧

Colchester, United Kingdom

Investigational Site Number 826-162

🇬🇧

Crawley, United Kingdom

Investigational Site Number 826-145

🇬🇧

Dafen, United Kingdom

Investigational Site Number 826-165

🇬🇧

Dumfries, United Kingdom

Investigational Site Number 826-167

🇬🇧

Durham, United Kingdom

Investigational Site Number 826-173

🇬🇧

East Kilbride, United Kingdom

Investigational Site Number 826-105

🇬🇧

Edinburgh, United Kingdom

Investigational Site Number 826-115

🇬🇧

Exeter, United Kingdom

Investigational Site Number 826-160

🇬🇧

Fleetwood, United Kingdom

Investigational Site Number 826-107

🇬🇧

Gateshead, United Kingdom

Investigational Site Number 826-174

🇬🇧

Haddington, United Kingdom

Investigational Site Number 826-120

🇬🇧

Ipswich, United Kingdom

Investigational Site Number 826-163

🇬🇧

Kirkcaldy, United Kingdom

Investigational Site Number 826-161

🇬🇧

Lancaster, United Kingdom

Investigational Site Number 826-101

🇬🇧

Liverpool, United Kingdom

Investigational Site Number 826-108

🇬🇧

Liverpool, United Kingdom

Investigational Site Number 826-142

🇬🇧

London, United Kingdom

Investigational Site Number 826-123

🇬🇧

London, United Kingdom

Investigational Site Number 826-156

🇬🇧

Mortimer, United Kingdom

Investigational Site Number 826-138

🇬🇧

Newport, United Kingdom

Investigational Site Number 826-133

🇬🇧

Nottingham, United Kingdom

Investigational Site Number 826-121

🇬🇧

Nuneaton, United Kingdom

Investigational Site Number 826-129

🇬🇧

Plymouth, United Kingdom

Investigational Site Number 826-103

🇬🇧

St Helens, United Kingdom

Investigational Site Number 826-139

🇬🇧

St Leonards on Sea, United Kingdom

Investigational Site Number 826-111

🇬🇧

Stevenage, United Kingdom

Investigational Site Number 826-131

🇬🇧

Stirling, United Kingdom

Investigational Site Number 826-146

🇬🇧

Sunderland, United Kingdom

Investigational Site Number 826-128

🇬🇧

Westbury, United Kingdom

Investigational Site Number 826-117

🇬🇧

York, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath